GILEAD SCIENCES TO ACQUIRE MYOGEN, INC. FOR $2.5 BILLION

Gilead Sciences, Inc. and Myogen, Inc. announced today that the companies have signed a definitive agreement under which Gilead plans to acquire Myogen. The transaction has been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed by a cash merger in which Gilead would acquire any remaining outstanding Myogen common stock at $52.50 per share. Upon completion of the second-step merger, Myogen will become a wholly-owned subsidiary of Gilead. The value of the transaction is approximately $2.5 billion. The deal is expected to be dilutive to Gilead's earnings in 2007 and 2008, neutral in 2009 and accretive in 2010 and beyond. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061002005375&newsLang=en)